Format
Items per page

Send to:

Choose Destination

Search results

Items: 1 to 20 of 462

1.

Slow acetylator due to N-acetyltransferase enzyme variant

MedGen UID:
164207
Concept ID:
C0878587
Finding
2.

Thiopurine response

MedGen UID:
1609699
Concept ID:
CN971394
Sign or Symptom
3.

Atorvastatin response

MedGen UID:
450433
Concept ID:
CN077961
Sign or Symptom
4.

Lansoprazole response

MedGen UID:
1137997
Concept ID:
CN474477
Sign or Symptom
5.

Erlotinib response

MedGen UID:
450453
Concept ID:
CN077981
Sign or Symptom
6.

Clomipramine response

MedGen UID:
808077
Concept ID:
CN221256
Sign or Symptom
7.

Fluoxetine response

MedGen UID:
450456
Concept ID:
CN077984
Sign or Symptom
8.

Methadone response

MedGen UID:
808058
Concept ID:
CN221249
Sign or Symptom
9.

Oxcarbazepine response

MedGen UID:
965502
Concept ID:
CN282567
Sign or Symptom
10.

Desipramine response

MedGen UID:
851737
Concept ID:
CN233052
Sign or Symptom
11.

Glimepiride response

MedGen UID:
1105342
Concept ID:
CN437678
Sign or Symptom
12.

Gefitinib response

MedGen UID:
450459
Concept ID:
CN077987
Sign or Symptom
13.

Pantoprazole response

MedGen UID:
1139261
Concept ID:
CN474478
Sign or Symptom
14.

Glibenclamide response

MedGen UID:
1104724
Concept ID:
CN437679
Sign or Symptom
15.

Tolbutamide response

MedGen UID:
865155
Concept ID:
C4016718
Finding
16.

Malignant hyperthermia

MedGen UID:
802424
Concept ID:
CN209346
Finding
17.

Warfarin response

Warfarin is an oral anti-coagulant used world-wide to treat and prevent thrombotic disorders. While it is highly effective, it has a very narrow therapeutic index making it difficult to dose correctly. Genetic variants in both cytochrome P450-2C9 (CYP2C9) and vitamin K-epoxide reductase complex (VKORC1) enzymes, along with non-genetic factors, are known to affect warfarin dose variability. Patients with specific variants in the gene CYP2C9 (the primary warfarin-metabolizing enzyme), such as CYP2C9*2 and CYP2C9*3, may require a lower dose of warfarin as compared to patients without these variants. Patients with a specific variant in VKORC1 (the target enzyme of warfarin), known as -1639G>A or rs9923231, may require a lower warfarin dose as compared to patients who do not have this variant. The combination of CYP2C9 and VKORC1 genetic variants, along with clinical factors, can put some patients at risk for adverse events such as bleeding. Guidelines regarding the use of pharmacogenomic tests in dosing for warfarin have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium (CPIC) and are available on the PharmGKB website. [from PharmGKB]

MedGen UID:
148193
Concept ID:
C0750384
Finding
18.

Statin-induced myopathy

MedGen UID:
507347
Concept ID:
CN181199
Sign or Symptom
19.

Oxycodone response

MedGen UID:
808056
Concept ID:
CN221247
Sign or Symptom
20.

Statin causing adverse effect in therapeutic use

MedGen UID:
834044
Concept ID:
CN181223
Sign or Symptom
Format
Items per page

Send to:

Choose Destination

Supplemental Content

Find related data

Search details

See more...

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center